Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection

Vaccine

Volumn 29, Issue 11, 2011, Pages 2100-2109

  van Dissel, Jaap T ^a   Soonawala, Darius ^a   Joosten, Simone A ^a   Prins, Corine ^a   Arend, Sandra M ^a   Bang, Peter ^b   Tingskov, Pernille Nyholm ^b   Lingnau, Karen ^c   Nouta, Jan ^a   Hoff, Søren T ^b   Rosenkrands, Ida ^b   Kromann, Ingrid ^b   Ottenhoff, Tom H M ^a   Doherty, T Mark ^b   Andersen, Peter ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b STATENS SERUM INSTITUT   (Denmark)

^c INTERCELL AG   (Austria)

Author keywords

BCG; Clinical trial; LTBI; Tuberculosis; Vaccine

Indexed keywords

ANTIGEN 85B; ANTIGEN 85B EARLY SECRETORY ANTIGENIC TARGET 6; BCG VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; HYBRID PROTEIN; IC31; TUBERCULIN; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ANTIGEN SPECIFICITY; ARTICLE; BCG VACCINATION; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHEMA; FATIGUE; FEMALE; FEVER; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE SORENESS; LUNG TUBERCULOSIS; MALAISE; MALE; MYCOBACTERIUM TUBERCULOSIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SWELLING; T LYMPHOCYTE; TREATMENT RESPONSE; VACCINATION;

ADULT; ANTIBODIES, BACTERIAL; BCG VACCINE; DRUG COMBINATIONS; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; OLIGODEOXYRIBONUCLEOTIDES; OLIGOPEPTIDES; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUBERCULOSIS; TUBERCULOSIS VACCINES; YOUNG ADULT;

EID: 79951811069     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.135     Document Type: Article

References (30)

1. Maher D., Dye C., Floyd K., Pantoja A., Lonnroth K., Reid A., et al. Planning to improve global health: the next decade of tuberculosis control. Bull World Health Organ 2007, 85(5 (May)):341-347.
2. Andersen P., Doherty T.M. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005, 3(8 (August)):656-662.
3. Hanekom W.A., Dockrell H.M., Ottenhoff T.H., Doherty T.M., Fletcher H., McShane H., et al. Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med 2008, 5(7 (July 1)):e145.
4. Beresford B, Sadoff JC. Update on research and development pipeline: tuberculosis vaccines. Clin Infect Dis 2010;50(Suppl. 3 (May 15)):S178-83.
5. Kaufmann S.H., Hussey G., Lambert P.H. New vaccines for tuberculosis. Lancet 2010, 375(9731 (June 12)):2110-2119.
6. van Dissel J.T., Arend S.M., Prins C., Bang P., Tingskov P.N., Lingnau K., et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 2010, 28(20 (April 30)):3571-3581.
7. Davila J., Zhang L., Marrs C.F., Durmaz R., Yang Z. Assessment of the genetic diversity of Mycobacterium tuberculosis esxA, esxH, and fbpB genes among clinical isolates and its implication for the future immunization by new tuberculosis subunit vaccines Ag85B-ESAT-6 and Ag85B-TB10.4. J Biomed Biotechnol 2010, 208371. 2010.
8. Langermans J.A., Doherty T.M., Vervenne R.A., van der Laan T., Lyashchenko K., Greenwald R., et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 2005, 23(21 (April 15)):2740-2750.
9. Olsen A.W., Williams A., Okkels L.M., Hatch G., Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 2004, 72(10 (October)):6148-6150.
10. Williams A., Hatch G.J., Clark S.O., Gooch K.E., Hatch K.A., Hall G.A., et al. Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) 2005, 85(1-2 (January-March)):29-38.
11. Agger E.M., Rosenkrands I., Olsen A.W., Hatch G., Williams A., Kritsch C., et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine 2006, 24(26 (June 29)):5452-5460.
12. Kamath A.T., Valenti M.P., Rochat A.F., Agger E.M., Lingnau K., von Gabain A., et al. Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells. Eur J Immunol 2008, 38(5 (May)):1247-1256.
13. Lingnau K., Riedl K., von Gabain A. IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems. Expert Rev Vaccines 2007, 6(5 (October)):741-746.
14. Aichinger M.C., Ginzler M., Weghuber J., Zimmermann L., Riedl K., Schutz G., et al. Adjuvanting the adjuvant: facilitated delivery of an immunomodulatory oligonucleotide to TLR9 by a cationic antimicrobial peptide in dendritic cells. Vaccine 2010, (November 18).
15. Holten-Andersen L., Doherty T.M., Korsholm K.S., Andersen P. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun 2004, 72(3 (March)):1608-1617.
16. van de Vosse E., Hoeve M.A., Ottenhoff T.H. Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae. Lancet Infect Dis 2004, 4(12 (December)):739-749.
17. Wassie L., Demissie A., Aseffa A., Abebe M., Yamuah L., Tilahun H., et al. Ex vivo cytokine mRNA levels correlate with changing clinical status of Ethiopian TB patients and their contacts over time. PLoS One 2008, 3(1):e1522.
18. Agger E.M., Andersen P. Tuberculosis subunit vaccine development: on the role of interferon-gamma. Vaccine 2001, 2119(17-19 (March)):2298-2302.
19. Schmittel A., Keilholz U., Bauer S., Kuhne U., Stevanovic S., Thiel E., et al. Application of the IFN-gamma ELISPOT assay to quantify T cell responses against proteins. J Immunol Methods 2001, 247(1-2 (January 1)):17-24.
20. Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004, 82(5 (October)):488-496.
21. Doherty M., Wallis R.S., Zumla A. Biomarkers for tuberculosis disease status and diagnosis. Curr Opin Pulm Med 2009, 15(3 (May)):181-187.
22. Wallis R.S., Doherty T.M., Onyebujoh P., Vahedi M., Laang H., Olesen O., et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 2009, 9(3 (March)):162-172.
23. Agger E.M., Cassidy J.P., Brady J., Korsholm K.S., Vingsbo-Lundberg C., Andersen P. Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection. Immunology 2008, 124(2 (June)):175-185.
24. Doherty T.M., Dietrich J., Billeskov R. Tuberculosis subunit vaccines: from basic science to clinical testing. Expert Opin Biol Ther 2007, 7(10 (October)):1539-1549.
25. McKee A.S., Munks M.W., Macleod M.K., Fleenor C.J., Van Rooijen N., Kappler J.W., et al. Alum induces innate immune responses through macrophage and mast cell sensors but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 2009, (September 4).
26. Von Eschen K., Morrison R., Braun M., Ofori-Anyinam O., De Kock E., Pavithran P., et al. The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans. Hum Vaccine 2009, 5(7 (July)):475-482.
27. Weir R.E., Gorak-Stolinska P., Floyd S., Lalor M.K., Stenson S., Branson K., et al. Persistence of the immune response induced by BCG vaccination. BMC Infect Dis 2008, 8:9.
28. Baumann S., Nasser Eddine A., Kaufmann S.H. Progress in tuberculosis vaccine development. Curr Opin Immunol 2006, 18(4 (August)):438-448.
29. Seder R.A., Hill A.V. Vaccines against intracellular infections requiring cellular immunity. Nature 2000, 406(6797 (August 17)):793-798.
30. Lindenstrom T., Agger E.M., Korsholm K.S., Darrah P.A., Aagaard C., Seder R.A., et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009, 182(12 (June 15)):8047-8055.